Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174399
Title: | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study |
Author: | Strosberg, Jonathan Kunz, Pamela L. Hendifar, Andrew Yao, James Bushnell, David Kulke, Matthew H. Baum, Richard P. Caplin, Martyn Ruszniewski, Philippe Delpassand, Ebrahim Hobday, Timothy Verslype, Chris Benson, Al Srirajaskanthan, Rajaventhan Pavel, Marianne Mora Salvador, Jaume Berlin, Jordan Grande, Enrique Reed, Nicholas Seregni, Ettore Paganelli, Giovanni Severi, Stefano Morse, Michael Metz, David C. Ansquer, Catherine Courbon, Frédéric Al-Nahhas, Adil Baudin, Eric Giammarile, Francesco Taïeb, David Mittra, Erik Wolin, Edward O’Dorisio, Thomas M. Lebtahi, Rachida Deroose, Christophe M. Grana, Chiara M. Bodei, Lisa Öberg, Kjell Polack, Berna Degirmenci He, Beilei Mariani, Maurizio F. Gericke, Germo Santoro, Paola Erion, Jack L. Ravasi, Laura Krenning, Eric Netter-1 Study Group |
Keywords: | Tumors Càncer de fetge Tumors Liver cancer |
Issue Date: | 2-Mar-2020 |
Publisher: | Springer Nature |
Abstract: | Purpose: To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. Methods: In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results: Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions: 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11. |
Note: | Reproducció del document publicat a: https://doi.org/10.1007/s00259-020-04709-x |
It is part of: | European Journal of Nuclear Medicine and Molecular Imaging, 2020, vol. 47, num. 10, p. 2372-2382 |
URI: | http://hdl.handle.net/2445/174399 |
Related resource: | https://doi.org/10.1007/s00259-020-04709-x |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Strosberg2020_Article_ImpactOfLiverTumourBurdenAlkal.pdf | 601.04 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License